Shire - Guidance Update

                           Shire - Guidance Update

  PR Newswire

  DUBLIN, January 8, 2013

DUBLIN, January 8, 2013 /PRNewswire/ --

- Shire plc (LSE: SHP, NASDAQ: SHPG)

Angus Russell, Chief Executive Officer of Shire, will address investors today
at the JP Morgan Healthcare Conference in San Francisco. In his address he
will confirm that Shire expects to deliver double digit full year earnings
growth for 2012, and looking ahead, Shire is now increasingly confident of
meeting current consensus earnings expectations ^(1) for 2013.

Angus' presentation will be webcast live today, at 11:00 AM PST/2:00 PM

Investors can access the live webcast here

(1) Based on the most recent consensus estimates compiled by Consensus
Forecast Ltd, as of the date of this press release, of $6.69 Non GAAP diluted
earnings per ADS for the year ended 31 December 2013, included on Shire's
website ( ).

Notes to editors

Shire enables people with life-altering conditions to lead better lives.

Through our deep understanding of patients' needs, we develop and provide
healthcare in the areas of:

  *Behavioral Health and Gastro Intestinal conditions
  *Rare Diseases
  *Regenerative Medicine

as well as other symptomatic conditions treated by specialist physicians.

We aspire to imagine and lead the future of healthcare, creating value for
patients, physicians, policymakers, payors and our shareholders.


Statements included herein that are not historical facts are forward-looking
statements. Such forward-looking statements involve a number of risks and
uncertainties and are subject to change at any time. In the event such risks
or uncertainties materialize, the Company's results could be materially
adversely affected. The risks and uncertainties include, but are not limited
to, risks associated with: the inherent uncertainty of research, development,
approval, reimbursement, manufacturing and commercialization of the Company's
Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine
products, as well as the ability to secure new products for commercialization
and/or development; government regulation of the Company's products; the
Company's ability to manufacture its products in sufficient quantities to meet
demand; the impact of competitive therapies on the Company's products; the
Company's ability to register, maintain and enforce patents and other
intellectual property rights relating to its products; the Company's ability
to obtain and maintain government and other third-party reimbursement for its
products; and other risks and uncertainties detailed from time to time in the
Company's filings with the Securities and Exchange Commission.

For further information please contact: Investor Relations Eric Rojas +1-781-482-0999Sarah Elton-Farr
+44-1256-894157 Media Jessica Mann +44-1256-894-280Gwen Fisher +1-484-595-9836
Press spacebar to pause and continue. Press esc to stop.